Figure 8.
![The plasma NMR metabolite profiles of patients treated with [A] oral 5-ASA and [B] oral 5-ASA [black] are evenly spread through the untreated samples [open circle] in the OPLS-DA scores plots.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/ecco-jcc/12/11/10.1093_ecco-jcc_jjy101/2/jjy10108.jpeg?Expires=1749468613&Signature=Q3MuylsFsJLJjcM3qB6~8cmNThFor2gGaZWs44Xeu~gho2HtaMpzQZVjVq2H97N45irNKdryB6pumQ1l7WOMdZm0bogv9n7jT7eQ5V6CnKGtoS2GIdFgIskNOvb8sNKm0t1ctPXZy2P212Dh3~hCLTA9KxPfublr5-xYSuTmWx0NbF2jeGj6fWaGekaKDlIUa1N6Kqm-Cutqi89aw0xRIvXsjS5ubHc89cwc1KugIHHoTBEhQJXtECn5uE-CCLaHlsTYJlJEOwDXIchSwFhTqKiO3AFfv9AAu7EK8UVB-978CMYQYUw1NomYZKNBQoE1G6ZRpb4Uw2WYwtNhAYmg8Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
The plasma NMR metabolite profiles of patients treated with [A] oral 5-ASA and [B] oral 5-ASA [black] are evenly spread through the untreated samples [open circle] in the OPLS-DA scores plots.
The plasma NMR metabolite profiles of patients treated with [A] oral 5-ASA and [B] oral 5-ASA [black] are evenly spread through the untreated samples [open circle] in the OPLS-DA scores plots.
